CoChat
Sign Up
Cited by 335

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Carbone, Michele, Adusumilli, Prasad S., Alexander, H. Richard, Baas, Paul, Bardelli, Fabrizio, Bononi, Angela, Bueno, Raphael, Felley‐Bosco, Emanuela, Galateau‐Salle, Francoise, Jablons, David, Mansfield, Aaron S., Minaai, Michael, de Perrot, Marc, Pesavento, Patricia, Rusch, Valerie, Severson, David T., Taioli, Emanuela, Tsao, Anne, Woodard, Gavitt, Yang, Haining, Zauderer, Marjorie G., Pass, Harvey I.·2019·CA: A Cancer Journal for Clinicians
DOI 10.3322/caac.21572PMC PMC8192079
Open this paper in CoChat — free account

Abstract

Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high‐resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1‐asssociated protein 1 ( BAP1 ) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3322/caac.21572

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 204

  1. 10.1016/S1470-2045(13)70257-2 · DOI
  2. 10.1016/j.jtho.2016.04.028 · DOI
  3. 10.1007/s10552-009-9357-4 · DOI
  4. 10.1038/modpathol.2017.108 · DOI
  5. 10.5858/arpa.2017-0365-RA · DOI
  6. 10.1080/10937404.2016.1195322 · DOI
  7. 10.1002/ajim.22955 · DOI
  8. 10.1038/sj.bjc.6603293 · DOI
  9. 10.1016/j.athoracsur.2014.04.040 · DOI
  10. 10.15585/mmwr.mm6608a3 · DOI
  11. Ferlay J, 2018, Global Cancer Observatory: Cancer Today
  12. 10.1016/j.jtho.2017.04.002 · DOI
  13. 10.1146/annurev-publhealth-031811-124704 · DOI
  14. 10.1111/1759-7714.12967 · DOI
  15. 10.1016/j.jss.2015.01.043 · DOI
  16. 10.1038/bjc.2014.478 · DOI
  17. 10.1016/j.jtho.2018.04.023 · DOI · Paper page
  18. 10.1001/jamaoncol.2016.5487 · DOI
  19. 10.1016/j.jtho.2016.12.006 · DOI
  20. Gilg Soit Ilg A, 2015, Programme national de surveillance du mesotheliome (PNSM). Actualisation des principaux resultats, Bull Epidemiol Hebd (BEH), 28
  21. 10.1136/oemed-2017-104383 · DOI · Paper page
  22. Sluis‐Cremer GK, 1992, The mortality of amphibole miners in South Africa, 1946‐80, Br J Ind Med., 49, 566
  23. 10.3109/01913129709021930 · DOI
  24. 10.1080/10408440701845609 · DOI · Paper page
  25. 10.1073/pnas.1105887108 · DOI · Paper page
  26. 10.1002/jcp.22724 · DOI
  27. 10.1038/nrc2068 · DOI
  28. 10.21037/atm.2017.04.06 · DOI
  29. 10.1016/j.ijheh.2017.07.003 · DOI
  30. 10.1136/oemed-2013-101957 · DOI
  31. 10.1097/JTO.0000000000000506 · DOI · Paper page
  32. 10.1080/10937404.2016.1195321 · DOI
  33. Carbone M, 2000, Simian virus 40: the link with human malignant mesothelioma is well established, Anticancer Res., 20, 875
  34. 10.1038/nrc947 · DOI
  35. 10.1073/pnas.170207097 · DOI
  36. 10.1177/1947601910395580 · DOI
  37. 10.1158/0008-5472.CAN-05-2028 · DOI
  38. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2014, Malaria and some polyomaviruses (SV40, BK, JC, and Merkel cell viruses), IARC Monogr Eval Carcinog Risks Hum, 104, 9
  39. Institute of Medicine Immunization Safety Review Committee, 2002, Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer
  40. Reger R, 1990, On talc, tremolite, and tergiversation, Br J Ind Med., 47, 505
  41. 10.1179/2049396714Y.0000000081 · DOI
  42. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010, Carbon black, titanium dioxide, and talc, IARC Monogr Eval Carcinog Risks Hum, 93, 1
  43. 10.1097/CEJ.0000000000000340 · DOI
  44. 10.1080/10408440903044928 · DOI
  45. 10.1016/0165-4608(89)90105-2 · DOI
  46. 10.1073/pnas.0604008103 · DOI · Paper page
  47. 10.1073/pnas.1006542107 · DOI · Paper page
  48. Xu A, 1999, Role of oxyradicals in mutagenicity and DNA damage induced by crocidolite asbestos in mammalian cells, Cancer Res., 59, 5922
  49. 10.1016/j.ajpath.2013.07.029 · DOI
  50. 10.18632/oncotarget.22968 · DOI
  51. 10.1165/rcmb.2007-0206OC · DOI
  52. 10.1038/nrc3703 · DOI
  53. 10.1126/science.1260825 · DOI · Paper page
  54. 10.1126/science.aaf9011 · DOI
  55. 10.1038/nature16166 · DOI
  56. 10.1038/s41467-018-05467-z · DOI
  57. 10.1038/jid.2010.302 · DOI
  58. 10.1126/science.aau3879 · DOI · Paper page
  59. 10.1038/s41418-018-0213-5 · DOI
  60. 10.1158/0008-5472.CAN-04-0255 · DOI
  61. 10.1016/S0140-6736(00)04013-7 · DOI
  62. 10.1038/ng.912 · DOI · Paper page
  63. 10.1200/JCO.2018.79.0352 · DOI
  64. 10.1200/JCO.2018.78.5204 · DOI
  65. 10.1073/pnas.1821510116 · DOI
  66. 10.1126/science.1221711 · DOI
  67. 10.1158/0008-5472.CAN-04-2260 · DOI
  68. 10.1186/1479-5876-10-179 · DOI
  69. 10.1371/journal.pgen.1005633 · DOI
  70. 10.1001/jamadermatol.2017.2330 · DOI
  71. 10.1093/jnci/djy171 · DOI
  72. 10.1038/nrc3459 · DOI · Paper page
  73. 10.1016/j.humpath.2014.10.015 · DOI
  74. 10.1097/JTO.0000000000000471 · DOI
  75. 10.1073/pnas.1612074113 · DOI
  76. 10.1158/0008-5472.CAN-14-1008 · DOI
  77. 10.1097/JTO.0000000000000436 · DOI
  78. 10.1038/ng.3520 · DOI
  79. 10.1073/pnas.1309085110 · DOI
  80. 10.1038/cdd.2017.95 · DOI · Paper page
  81. 10.1038/nature22798 · DOI
  82. 10.1038/s41556-018-0178-0 · DOI
  83. 10.1038/s41419-018-1206-5 · DOI
  84. 10.1038/onc.2015.243 · DOI
  85. 10.1186/s12967-014-0301-3 · DOI
  86. Oey H, Whole‐genome sequencing of human malignant mesothelioma tumours and cell lines [published online April 25, 2019], Carcinogenesis
  87. 10.1158/2159-8290.CD-18-0804 · DOI · Paper page
  88. Ugurluer G, 2016, Genome‐based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma, Anticancer Res., 36, 2331
  89. 10.1016/j.jtho.2018.10.001 · DOI
  90. 10.1016/j.jtho.2018.11.006 · DOI
  91. 10.1378/chest.11-3204 · DOI
  92. 10.1053/j.semdp.2006.08.002 · DOI
  93. 10.1097/JTO.0000000000000630 · DOI
  94. DeMay RM, 2011, The Art & Science of Cytopathology
  95. DeMay RM, 2011, The Art & Science of Cytopathology
  96. 10.1038/modpathol.2015.65 · DOI
  97. 10.1016/j.humpath.2016.09.026 · DOI
  98. 10.5858/arpa.2017-0124-RA · DOI
  99. 10.1136/oem.2005.023200 · DOI · Paper page
  100. 10.1016/j.humpath.2015.06.024 · DOI
  101. 10.18632/oncotarget.10653 · DOI
  102. 10.1016/j.humpath.2017.07.015 · DOI
  103. 10.1097/PAS.0000000000000825 · DOI
  104. 10.1016/j.molcel.2014.03.002 · DOI
  105. 10.5858/arpa.2015-0240-SA · DOI
  106. 10.1097/PAS.0000000000000394 · DOI
  107. 10.1111/his.13468 · DOI
  108. 10.1016/j.jtho.2016.06.020 · DOI
  109. 10.1097/PAS.0000000000000616 · DOI
  110. 10.1007/0-387-28274-2_33 · DOI
  111. Carbone M, 2002, Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications, Anticancer Res., 22, 3443
  112. 10.1016/j.jtcvs.2006.03.068 · DOI
  113. 10.1245/s10434-010-1107-z · DOI
  114. 10.1016/j.jtcvs.2004.10.034 · DOI
  115. 10.1007/BF02305768 · DOI
  116. 10.1016/j.ejcts.2003.12.001 · DOI
  117. 10.1158/1078-0432.CCR-07-5283 · DOI
  118. 10.1378/chest.129.6.1570 · DOI
  119. 10.1148/radiol.12110872 · DOI
  120. 10.2214/ajr.172.4.10587144 · DOI
  121. 10.1016/j.athoracsur.2009.05.022 · DOI
  122. 10.1097/JTO.0b013e31826915f1 · DOI · Paper page
  123. 10.1016/j.jtho.2016.08.147 · DOI
  124. 10.1378/chest.108.4.1122 · DOI
  125. 10.1016/j.jtho.2016.09.121 · DOI
  126. 10.1016/j.jtho.2016.09.124 · DOI
  127. 10.1016/j.athoracsur.2016.06.069 · DOI
  128. 10.1016/j.jtho.2016.04.027 · DOI
  129. 10.1097/JTO.0b013e318211127a · DOI
  130. 10.1016/j.annepidem.2017.04.001 · DOI
  131. 10.1200/JCO.1998.16.1.145 · DOI
  132. 10.1378/chest.113.3.723 · DOI
  133. 10.1016/j.jtho.2015.12.108 · DOI
  134. 10.1097/JTO.0000000000000181 · DOI
  135. 10.1016/j.lungcan.2016.09.003 · DOI
  136. 10.1183/13993003.01428-2016 · DOI
  137. 10.1093/carcin/bgu227 · DOI
  138. 10.1016/j.canlet.2017.06.028 · DOI · Paper page
  139. 10.1016/S1470-2045(17)30891-4 · DOI
  140. 10.1016/j.critrevonc.2016.05.008 · DOI
  141. 10.1038/bjc.2014.418 · DOI
  142. 10.1007/s10689-006-9112-x · DOI
  143. 10.1016/S1470-2045(16)30525-3 · DOI
  144. 10.1097/JTO.0b013e3182208e3f · DOI
  145. 10.1097/SLA.0000000000000903 · DOI
  146. 10.1016/j.jtcvs.2007.10.054 · DOI
  147. 10.1200/JCO.2017.76.6394 · DOI
  148. 10.1097/JTO.0b013e31815608d9 · DOI
  149. 10.1016/j.lungcan.2013.11.026 · DOI
  150. 10.1016/j.athoracsur.2007.06.066 · DOI
  151. 10.1016/S1470-2045(11)70149-8 · DOI
  152. 10.1016/j.athoracsur.2014.06.024 · DOI
  153. 10.1016/j.jtcvs.2015.09.121 · DOI
  154. 10.1016/j.athoracsur.2014.09.056 · DOI
  155. 10.1007/s10147-015-0925-1 · DOI
  156. 10.1158/1078-0432.CCR-17-0438 · DOI
  157. 10.18632/oncotarget.3487 · DOI
  158. 10.1097/JTO.0000000000000078 · DOI
  159. 10.1016/j.jtho.2018.08.419 · DOI
  160. 10.1016/S1470-2045(17)30459-X · DOI
  161. 10.1007/s00066-017-1108-y · DOI
  162. 10.1245/ASO.2003.03.022 · DOI
  163. 10.1016/j.surg.2013.01.001 · DOI
  164. 10.1007/BF02303538 · DOI
  165. 10.1038/bjc.1997.468 · DOI
  166. 10.1016/S0003-4975(02)04474-0 · DOI
  167. 10.1200/JCO.2003.11.136 · DOI · Paper page
  168. 10.1016/S0140-6736(15)01238-6 · DOI · Paper page
  169. 10.1016/j.jtho.2018.08.2036 · DOI
  170. 10.1080/2162402X.2015.1009285 · DOI
  171. 10.1016/j.jtho.2016.06.022 · DOI · Paper page
  172. 10.1007/s00262-011-1073-8 · DOI
  173. 10.1097/JTO.0000000000000177 · DOI
  174. 10.1016/j.jtho.2018.06.011 · DOI
  175. 10.1016/S1470-2045(17)30169-9 · DOI
  176. 10.1016/j.jtho.2018.08.276 · DOI
  177. 10.1016/j.jtho.2018.08.007 · DOI
  178. 10.21037/tlcr.2017.05.02 · DOI
  179. 10.1016/S1470-2045(15)70056-2 · DOI
  180. 10.1038/nm.3947 · DOI
  181. 10.1038/s41467-018-06854-2 · DOI
  182. 10.1016/j.jtho.2018.02.021 · DOI
  183. 10.1016/j.bmcl.2017.05.077 · DOI
  184. 10.1016/j.jtho.2017.03.023 · DOI
  185. 10.1007/s00280-017-3401-y · DOI
  186. Okonska A, Genome‐wide silencing screen in mesothelioma cells reveals that loss of function of BAP1 induces chemoresistance to ribonucleotide reductase inhibition: implication for therapy [published online July 31, 2018], bioRxiv
  187. 10.3390/ijms20020429 · DOI
  188. 10.1097/PAT.0b013e3283631cce · DOI
  189. 10.1097/PAT.0000000000000181 · DOI
  190. 10.1378/chest.06-1690 · DOI
  191. 10.1136/oem.2004.018531 · DOI
  192. 10.1001/jamaoncol.2017.2918 · DOI
  193. Alexander HR, 2007, Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma, Cancer Treat Res., 134, 343
  194. 10.4149/neo_2014_053 · DOI
  195. 10.1245/s10434-014-3978-x · DOI
  196. 10.1093/annonc/mdp307 · DOI
  197. 10.1245/s10434-012-2236-3 · DOI
  198. 10.1016/j.ejca.2013.05.027 · DOI
  199. 10.1200/JCO.2009.23.9640 · DOI
  200. 10.1245/s10434-014-3803-6 · DOI

200 of 204 shown

Cited by

Sorted by citations

Metadata

Authors
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., Mansfield, A. S., Minaai, M., de Perrot, M., Pesavento, P., Rusch, V., Severson, D. T., Taioli, E., Tsao, A., Woodard, G., Yang, H., Zauderer, M. G., & Pass, H. I.
Affiliations
  • Thoracic Oncology Program University of Hawaii Cancer Center Honolulu Hawaii
  • Thoracic Service, Department of Surgery Memorial Sloan Kettering Cancer Center New York New York
  • Department of Surgery Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey
  • Department of Thoracic Oncology Netherlands Cancer Institute Amsterdam Netherlands
  • National Research Council Institute of Nanotechnology La Sapienza University Rome Italy
  • Division of Thoracic Surgery, Department of Surgery, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts
  • Laboratory of Molecular Oncology, Division of Thoracic Surgery University Hospital of Zurich Zurich Switzerland
  • MESOPATH, Department of Biopathology Leon Bernard Cancer Center Lyon France
  • Thoracic Oncology, Department of Surgery, Helen Diller Cancer Center University of California at San Francisco San Francisco California
  • Division of Medical Oncology Mayo Clinic Rochester Minnesota
  • Princess Margaret Cancer Center University Health Network Toronto Ontario Canada
  • Pathology, Immunology, and Microbiology Laboratory University of California at Davis Sacramento California
  • Translational Epidemiology and Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai New York New York
  • Division of Cancer Medicine, Department of Thoracic and Head/Neck Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas
  • Thoracic Oncology Memorial Sloan Kettering Cancer Center New York New York
  • Department of Cardiothoracic Surgery New York University Langone Medical Center New York New York
ORCID
Carbone, Michele
Venue
CA: A Cancer Journal for Clinicians
Publisher
Wiley
Published
2019-07-08
Volume
69
Issue
5
Pages
402-429
ISSN
  • 0007-9235
  • 1542-4863
DOI
10.3322/caac.21572
PMC
PMC8192079
Cited by
335
References
4
Language
en
Update notices
erratum (2020-03-06)
Licence
Funders
  • National Cancer Institute (1R01CA198138-01)
  • V Foundation for Cancer Research
  • U.S. Department of Defense (W81XWH-16-1-0344, W81XWH-16-1-0441)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review